Dmytro Kharkov

AbbVie growth drugs support stock buy case as Humira transition eases

AbbVie growth drugs support stock buy case as Humira transition eases
New drugs boost AbbVie

AbbVie is entering a new phase of expansion as newer medicines offset the long decline in Humira sales and add momentum across key therapy areas. The company’s immunology and neuroscience portfolios are driving double-digit revenue growth, while its dividend and profitability continue to support the investment case.

Highlights

  • Skyrizi and Rinvoq combined post over $8 billion in Q2 revenue, surpassing Humira's $756 million and driving AbbVie's immunology transition.
  • AbbVie Q2 revenue rises 10.2% to about $17 billion, adjusted EPS up nearly 23% to $3.65 with a strong 48.3% adjusted operating margin.
  • Neuroscience revenue grows more than 20% to about $3.2 billion, while aesthetics revenue remains flat at $1.28 billion as Juvéderm sales decline 6%.

Portfolio shift drives earnings momentum

As reported by CNBC, the investment case for AbbVie is increasingly centered on the strength of its post-Humira drug portfolio rather than on its legacy blockbuster. Humira lost U.S. exclusivity in 2023, but Skyrizi and Rinvoq are now emerging as the company’s main growth engines and are helping replace the revenue that has been lost.

In the second quarter, Skyrizi sales rise 24.4% to $5.5 billion, while Rinvoq revenue increases 24.5% to $2.5 billion. Together, the two drugs generate more than $8 billion in quarterly revenue, far above the $756 million reported from Humira, underscoring how AbbVie’s transition in immunology is progressing.

AbbVie’s second-quarter revenue increases 10.2% to about $17 billion, while adjusted earnings per share jump nearly 23% to $3.65. The company also reports an adjusted operating margin of 48.3%, a level that indicates the drugmaker is sustaining strong profitability even as it reshapes its product mix.

Diversification supports longer-term outlook

Neuroscience is adding another meaningful source of growth for AbbVie. Second-quarter revenue in that business rises more than 20% to about $3.2 billion, supported by products including Vraylar, migraine treatments Ubrelvy and Qulipta, Botox Therapeutic and Vyalev for certain patients with advanced Parkinson’s disease.

The company also retains diversification through its aesthetics unit, Allergan Aesthetics, which includes Botox Cosmetic and Juvéderm. That business is not currently the fastest-growing part of AbbVie, with second-quarter aesthetics revenue essentially flat at about $1.28 billion and Juvéderm sales down 6%, but it still provides exposure to consumer demand for minimally invasive cosmetic procedures.

At about $280 a share, AbbVie trades at roughly 20 times management’s latest 2026 adjusted earnings guidance, based on the investor’s assessment in the source text. The stock also offers a quarterly dividend of $1.73 per share, or $6.92 annually, for a yield of roughly 2.5%, although risks remain from reliance on Skyrizi and Rinvoq, competition, drug pricing pressure and future patent expirations.

In our earlier article on the S&P 500’s push toward 8,000, we explained how investors were weighing whether strong third-quarter earnings could offset headwinds from higher oil prices, elevated Treasury yields, and political uncertainty. We also noted growing concerns about market concentration in a handful of mega-cap leaders and signs of weakening breadth, which has prompted some strategists to rotate allocations away from U.S. tech and toward areas such as healthcare.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.